Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Fig. 1

High-throughput immune assessment for biomarker discovery and personalized cancer immunotherapy. Immunologically-ignorant and immunologically-responsive tumors are classified by the presence of immune cells in the tumor microenvironment. Potential biomarkers identified from high-throughput technologies can further differentiate these tumors by the mutation load, gene/protein/antibody signature profile, phenotype and function of immune cells, and can also provide clinical strategies for personalized cancer immunotherapies. The new and innovative technologies that can be utilized to identify potential biomarkers include whole exome sequencing, gene signature, epigenetic modification, protein microarray, B/T cell receptor repertoire, flow/mass cytometry and multicolor IHC. Arrows indicate a decrease (↓) or increase (↑)

Back to article page